Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (AZNCF)
OTHER OTC:AZNCF
Holding AZNCF?
Track your performance easily
AZNCF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$118.16 - $175.00
Previous Close$168.98
Volume526.00
Average Volume (3M)1.78K
Market Cap
$255.29B
Enterprise Value$278.10B
Total Cash (Recent Filing)$5.84B
Total Debt (Recent Filing)$28.62B
Price to Earnings (P/E)39.6
Beta0.52
Next Earnings
Nov 12, 2024EPS Estimate
$2.1Last Dividend Ex-Date
Aug 08, 2024Dividend Yield1.86%
Share Statistics
EPS (TTM)4.16
Shares Outstanding1,550,286,637
10 Day Avg. Volume869
30 Day Avg. Volume1,784
Standard Deviation0.06
R-Squared0.15
Alpha0.00932
Financial Highlights & Ratios
Price to Book (P/B)-12.18
Price to Sales (P/S)5.20
Price to Cash Flow (P/CF)22.90
P/FCF Ratio32.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.27
Enterprise Value/Gross Profit7.41
Enterprise Value/Ebitda30.61
Forecast
1Y Price Target
$179.97Price Target Upside6.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
AstraZeneca News
PremiumCompany Announcements
AstraZeneca Shares and Voting Rights Update
Bulls Say, Bears Say
Bulls Say
Clinical Trials And DataCalquence's recent positive Phase III data presents a blockbuster opportunity and a key near-term growth opportunity.
Guidance And ForecastsA significant upgrade to 2024 guidance on the top and bottom line is expected to be positively received, increasing confidence in Astra’s strong medium- and long-term outlook.
Sales PerformanceSales estimates were raised, suggesting room for upside.
Bears Say
CompetitionJNJ's SubQ Rybrevant represents a more convenient and tolerable offering than IV, which will likely increase the competitive profile for MARIPOSA in 1L NSCLC vs. Tagrisso.
EarningsQ2 Core EPS forecast is 2% below Consensus, primarily due to higher tax.
Product ExpectationsEnthusiasm for the TROP2 ADC class has moderated, and Dr. Herbst's expectations for a broad benefit in the first-line setting have also been tempered by data presented to date.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.16% Insiders
15.00% Mutual Funds
8.55% Other Institutional Investors
76.29% Public Companies and
Individual Investors
AZNCF FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest stock price was $118.16 and its highest was $175.00 in the past 12 months.
What is AstraZeneca PLC’s market cap?
Currently, no data Available
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Nov 12, 2024 which is in 65 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Jul 25, 2024. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.965 by $0.015.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Annually dividend of $1.05 which represents an annual dividend yield of 1.86%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is $2.1.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,286,600 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of $1.98 in its last earnings report, beating expectations of $1.965. Following the earnings report the stock price went down -1.126%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in AZNCF
---
AstraZeneca Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$179.97 (6.51% Upside)
$179.97 (6.51% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.88%
12-Months-Change
Fundamentals
Return on Equity
16.83%
Trailing 12-Months
Asset Growth
8.70%
Trailing 12-Months
Company Description
AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
---
AZNCF Stock 12 Month Forecast
Average Price Target
$179.97
▲(6.51% Upside)
Technical Analysis
AstraZeneca
―
GlaxoSmithKline
―
Hikma Pharmaceuticals
―
Indivior
―
EKF Diagnostics Holdings
―
Best Analysts Covering AZNCF
1 Year
1 Year Success Rate
21/24 ratings generated profit
1 Year Average Return
+14.28%
reiterated a buy rating last month
Copying Sachin Jain's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +14.28% per trade.
---